Greetings, ladies and gentlemen, and welcome to the Balchem Corporation Q1 2021 earnings conference call. It is now my pleasure to introduce your host, Mr. Martin Bengtsson. Thank you for staying. You You may begin. Morning, everyone. Thank you for joining our conference call this morning to discuss the results of Balchem Corporation for the quarter ending March 31st, 2021. My name's Martin Bengtsson, Chief Financial Officer, and hosting this call with me is Ted Harris, our Chairman, CEO, and President. Following the advice of our counsel, auditors, and the SEC, at this time, I would like to read our forward-looking statement. This release does contain or likely will contain forward-looking statements, which reflect Balchem's expectation or belief concerning future events that will involve risks and uncertainties. We can give no assurance that the expectations reflected in forward-looking statements will prove correct, and various factors could cause results to differ materially from our expectations, including risks and factors identified in Balchem's Form 10-K. Forward-looking statements are qualified in their entirety by this cautionary statement. I will now turn the call over to Ted Harris, our Chairman, CEO, and President. Thanks, Martin. Good morning, and welcome to our conference call. This morning, we reported strong Q1 results with solid revenue growth, earnings growth, and free cash flow growth. Our revenues of $185.7 million were up 6.4%. Our adjusted earnings from operations were $37.3 million, up 7.5% versus the prior year quarter. Our Q1 net income of $23.4 million, an increase of 18.4%, resulted in earnings per share of $0.72 on a GAAP basis. On an adjusted basis, our Q1 non-GAAP net earnings were $28.4 million, or $0.87 per share, an increase of 7.1%. We continued to deliver strong cash flows. Cash from operations was $40.6 million for the Q1 of 2021, with quarterly free cash flow of $34.4 million, an increase of 97.7% compared to the prior year quarter. Overall, a great start to 2021. While there are many challenges to manage in the overall macroeconomic environment at the moment, these results highlight the strength and resilience of our business model. Before passing the call back to Martin to cover the detailed financial results, I would like to update you on the impact of COVID-19 on our company, as well as a few of our important strategic activities and growth initiatives. It is incredible to think that it has been more than one year that we have all been living with the COVID-19 pandemic and all of the related challenges it has created. This time last year, we were talking with you about our early response actions of activating our crisis management team, halting domestic and international travel, implementing new strict safety protocols at our manufacturing sites, working from home for our office employees, and stress testing our balance sheet to ensure we could withstand extreme scenarios as we headed into the market uncertainties ahead of us, just to name a few. While the COVID-19 pandemic is certainly not behind us yet and our priorities remain the same, employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate. We are extremely pleased with our response to the pandemic and ultimately the performance of the company in light of the challenges we have faced. We have indeed responded well to the changes in this dynamic market environment, and we are today having to respond to new challenges that are at least partly related to the pandemic as well as the economic recovery regarding significantly higher raw material and freight costs. While we don't believe these cost increases are differentially impacting Balchem, We are having to dedicate significant resources to various mitigating activities to effectively manage through this aspect of the pandemic and macroeconomic environment, just as we have through all previous challenges stemming from the pandemic. Moving on to a few highlights relative to our important strategic activities and growth initiatives. Within our Animal Nutrition and Health segment, the launch of AminoShure-XM, our next generation rumen-protected methionine for the dairy market, continues to go well as the product is gaining acceptance with progressive dairy producers who are looking to maximize profitability by growing the milk protein portion of their output. Additionally, our companion animal team has been working hard to grow our PetShure line of products, including several sensory-related products, and we are excited to have one of these PetShure sensory products included in a recently launched fruit-flavored dog treat product by a leading brand. We continue to be bullish about the companion animal market and our ability to bring differentiated solutions to solve the new and developing needs of the market. To that end, we had a large number of Balchem-sponsored research trials relating to our PetShure line of products that have been submitted for presentation at scientific meetings in 2021. We are also celebrating today our one-year anniversary of the Real Science Lecture Series, which has now expanded to include all three species segments, ruminants, swine and poultry, and companion animals. These educational and science-based webinars have been hugely successful, attracting over 8,000 live attendees and over 17,000 people have watched the recorded sessions. This pivot of our marketing approach during the pandemic has enabled us to effectively reach and interact with an expanded target audience despite the pandemic. Speaking of marketing approaches, as we have talked about in the past, our Human Nutrition and Health segment has strengthened its marketing capabilities to accelerate awareness around existing science and to better showcase to our customers through marketing campaigns how they can incorporate and benefit from our products. This year, we launched three new marketing campaigns. The first was focused on the benefits of our Albion branded chelated magnesium as a solution for sleep and relaxation. The second showcased the importance of choline in a prenatal vitamin regimen. The third was a new food campaign that was based on proprietary market research focused on consumer interest around products featuring our novel inclusions for baked goods applications. In the coming months, we'll be highlighting campaigns around immunity, cognition, and our enhanced capabilities in protein crisps and beverages. We are excited by how these campaigns are already creating opportunities by developing new leads and building loyalty amongst existing customers. In the quarter, we also continued to progress our efforts to consolidate all of our ERP systems into one, Microsoft Dynamics 365. This initiative is critical for the continued growth and operational efficiency of the company. We successfully added one more site to the new system in the quarter, leaving just two international sites left on legacy systems. We now have approximately 96% of our revenues on the new system and remain on track to complete implementation of the project this year. In our continuing effort to advance our environmental, social, and governance or ESG efforts, recently, Balchem proudly signed the CEO Action for Diversity & Inclusion pledge as a further commitment to advance diversity and inclusion within our workplace. The CEO Action for Diversity & Inclusion outlines a specific set of actions the signatory CEOs will take to cultivate a trusting environment where all ideas are welcome and employees feel comfortable and empowered to have discussions about diversity and inclusion. Just earlier this week, we released our third sustainability report, which captures the company's commitment to managing our ESG performance. This report demonstrates the company's continuing promise to provide our employees, customers, shareholders, and the communities within which we operate with information on Balchem sustainability initiatives. Of particular note, in this year's report, we have, for the first time, published our 2030 goals to reduce both greenhouse gas emissions and water usage by 25% by that date. We are very proud of the report and the progress we have been making. I would encourage you to go to balchem.com to read the report. While on the balchem.com website, you will also notice that our website was recently updated, consolidating all of our many legacy Balchem websites into one with a more modern look, feel, and navigation capability that should serve us well as we continue to grow and become more global. I'm now going to turn the call back over to Martin to go through the detailed financial results and the results for each of our individual segments. Martin? Thank you, Ted. As Ted mentioned, we delivered overall strong financial results in a challenging environment. Our Q1 net sales of $185.7 million were 6.4% higher than the prior year comparable quarter. We delivered record sales in our Human Nutrition and Health and Animal Nutrition and Health segments, while showing sequential improvement and slight year-over-year growth in the Specialty Product segment. The impact of foreign exchange to our sales was a positive $2.4 million, primarily due to the stronger euro, contributing a positive 1.35% impact to our year-over-year sales growth. Our Q1 consolidated gross margin dollars of $58.7 million were up $3.4 million or 6.1%, compared with $55.3 million for the same period in the prior year. Our consolidated gross margin percent was 31.6% of sales in the quarter, down nine basis points compared to 31.7% in the Q1 of 2020. The nine basis points decrease was primarily due to a significant increase in certain raw material and distribution costs, partially offset by favorable mix and manufacturing efficiencies. Consolidated operating expenses for the Q1 of 2021 were $28.2 million as compared to $29.1 million in the prior year. The decrease was principally due to a decrease in transaction and integration costs, travel, bad debt, and amortization, partially offset by certain higher compensation-related costs. Looking forward, we will continue to focus on controlling our operating expenses and leveraging our existing SG&A infrastructure where possible. GAAP earnings from operations for the Q1 were $30.6 million, an increase of $4.3 million or 16.4% compared to the prior year quarter. On an adjusted basis, as detailed in our earnings release this morning, non-GAAP earnings from operations of $37.3 million were up $2.6 million or 7.5% compared to $34.7 million in the prior year. Record adjusted EBITDA of $45.7 million was $3.4 million or 7.9% above the Q1 of 2020. Interest expense for the Q1 of 2021 was $0.7 million, and our net debt was $65 million with an overall leverage ratio on a net debt basis of 0.4. The company's effective tax rates for the Q1 of 2021 and 2020 were 21.9% and 19.3% respectively. The increase in the effective tax rate was primarily due to reduction in certain tax credits and higher effective tax rates in several states within the United States. Consolidated net income closed the quarter at $23.4 million, up 18.4% from the prior year quarter. This quarterly net income translated into diluted net earnings per share of $0.72 for the current year, an increase of $0.11 or 17.9% from last year's comparable quarter. On an adjusted basis, our Q1 adjusted net earnings were $28.4 million or $0.87 per diluted share, up $2 million or 7.6% compared with the prior year quarter. We generated quarterly free cash flow of $34.4 million, up 98% compared to the prior year quarter, and we closed out the quarter with $88.5 million of cash on the balance sheet. As we look at it from a segment perspective, for the quarter, our Human Nutrition & Health segment generated record quarterly sales of $104.5 million, an increase of $9 million or 9.4% from the prior year. The sales increase was driven both by strong sales growth of chelated minerals and choline nutrients, as well as higher sales within food and beverage markets. Our minerals and choline nutrients business saw increased demand when the COVID-19 pandemic started last year, and there have been no signs of any slowdown to date. In fact, the last two quarters have shown sequential growth in this part of the portfolio, and we're pleased to see the increased awareness around the health benefits of these products. We were also pleased to see the growth on the food ingredient side of our business, where we are seeing a modest but steady improvement in food service, along with the gradual reopening of our economy. Our Human Nutrition and Health segment also delivered record quarterly earnings from operations of $19.7 million, an increase of $7.6 million or 62.3% compared to prior year, primarily due to the aforementioned higher sales, product mix, and manufacturing efficiencies, partially offset by higher raw material costs. Our Animal Nutrition Health segment generated record quarterly sales of $51.1 million, an increase of 5.2% or $2.5 million compared to the prior year. Increase in sales was primarily the result of higher sales in both monogastric and ruminant animal markets, and a favorable impact related to changes in foreign exchange rates, which contributed $1.4 million or 2.8% of growth to the segment. Our ruminant business grew volumes 6.5%, and we continue to successfully drive penetration of our rumen-protected encapsulated products in the market. In terms of dairy economics, milk and milk protein prices continue to be volatile and have come down a bit during the Q1, but are still at relatively healthy levels. On the monogastric side, overall volumes were relatively flat with good growth in companion animals as well as U.S. feed-grade choline, but offset by lower European demand for choline. Animal Nutrition and Health quarterly earnings from operations of $5.1 million were down $3.0 million or 37.1% from the prior year quarter, primarily due to increases in raw material costs and distribution costs along with an unfavorable mix. We have arrangements in place to recover a significant portion of the raw material increases through price increases to our customers. However, there is a timing delay between the raw material inflation and the selling price adjustments, and there is on average a quarter delay. Our Specialty Product segment delivered quarterly sales of $28 million, up very slightly from the same quarter in 2020, primarily due to higher sales of products for the medical device sterilization market and a favorable impact related to changes in foreign currency exchange rates, offset by lower sales in the plant nutrition business. While volumes related to sales into the device sterilization markets were down on a year-over-year basis, it improved sequentially versus the Q4 of 2020, and it is encouraging to see gradual improvement as elective surgeries are slowly recovering. The specialty product segment had Q1 earnings from operations of $7.2 million versus $8.0 million in the prior quarter, a decrease from $0.8 million or 10%. The decrease was primarily due to increases in raw material costs and distribution costs. I'm now going to turn the call back over to Ted for some closing remarks. Thanks, Martin. We are extremely pleased with Balchem's financial results reported earlier this morning, and we certainly carry the positive momentum from 2020 into 2021. In the Q1 of 2021, we delivered all-time record revenues, with revenue growth in all three of our business segments, not only versus the prior year's quarter, but also sequentially versus the Q4 2020, reflecting a modest but gradual reopening of economies around the world. We achieved record Q1 consolidated GAAP net earnings, record quarterly non-GAAP adjusted net earnings, record adjusted EBITDA, and strong cash flows from operations while facing certain higher raw material and distribution costs and complexities associated with logistical disruptions. These very strong results reported today continue to show that we are well-positioned in attractive markets where we have the leadership and capabilities to be successful, not only today, but also into the future. I would now like to hand the call back over to Martin, who will open up the call for questions. Martin? Thank you, Ted. This now concludes the formal portion of the conference. At this point, we will open up the conference call for questions. Thank you. Ladies and gentlemen, if you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line's in the question queue. You may press star two if you'd like to remove your question from the queue. For parties using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. One moment please, while we call for questions. Our first question comes from the line of Bob Labick with CJS Securities. Please proceed with your question. Good morning, and congratulations on an excellent start to the year. Thanks, Bob. Thanks, Bob. I wanted to start with one of the things you mentioned in your prepared remarks. You talked about strengthening the marketing to accelerate awareness. Could you maybe expand upon that a little bit? Are you using new channels? Are you spending more dollars? Is this like a shift in dollars? Just what was the impetus behind this, and how should we think about where you were, where you are, and where you're going in this marketing campaigns? Yeah, we're really excited about the changes that we have made. I would say, overall, it's really more of a shift in dollars as opposed to a dramatic increase. We traditionally relied more on kind of basic advertising as well as the efforts of our sales organization. While the sales organization remains a critical part of building awareness, We've also now added to the team some real marketing expertise and capability and are paying for that a little bit with reduced advertising expense and are now able to do campaigns in-house. For example, some of the campaigns I talked about, we've recently really done on our own. We've added not only marketing expertise and leadership, we've added market research capabilities that we never had before. We're conducting focus groups and really kind of digging into the needs of the market and trying to target those needs with these campaigns. We're not spending a lot more than we used to. It's just really a shift in spend, building our own internal capabilities, and really pleased with the initial progress from all of that. Got it. That's great. Thank you. I know you highlighted this a little bit. I wanted to get a little more specific, in terms of margins. The H&H margins were, I think, or at least a couple of years, if not all-time high on the adjusted basis and adjusted EBIT basis. Obviously, A&H and specialty were more impacted by raw materials. The question is, one, what was the kind of driver of the H&H, and has anything materially changed for the long term? Or is this timing mix, et cetera? Just how should we start thinking about the recovery from the raw material pressures in A&H and specialty? Thanks. Yeah. Bob Labick, this is Martin Bengtsson. We take ANH first. We did see very strong margins here in the Q1, and it's primarily driven by favorable product mix in the sense that you have a very strong minerals and nutrients, which relatively speaking is higher margin compared to the food ingredients. As those minerals and nutrients are growing at very rapid rates, 20%, 30%, that drives that favorable mix that's helping the margin for them. In addition to that, they also had a strong manufacturing quarter. We have in the previous quarters, you remember Q3 and Q4 mentioned some of the inefficiencies we saw in the manufacturing operations negatively impacting them. Here in the Q1, as we worked through many of those issues, we saw an uptick and an improved performance, which also helped the margins for H&H. When we look at it to the second part of your question around ANH and SP, who are both significantly impacted by both raw materials and freight and distribution, they are a little bit experiencing what you're seeing around the world at the moment and that you hear many companies talk about. For a number of our key raw materials, it started to creep up a little bit in the Q4, but it really took off quite significantly in the Q1 in terms of material inflation. On our ability to price that through to our customers, we're usually in a, I would say, relatively good position to recapture that through pricing. Over time, we tend to see the margins come back to where they should be. It takes us a quarter and sometimes into two quarters to recapture that. Some of our pricing arrangements have language around index-based adjustments. Some of these indexes tie back to commodity indexes, so we can't do so much around the actual raw material inflation itself. We can adjust the pricing. There is a quarter lag. From the moment the prices plateau, so to speak, and stop increasing, it is at least a quarter to recapture it and sometimes extend to two quarters behind. It's on an upwards trend that creates margin pressure, and a downward trend, it helps margins in the same way. Over time, as we look at this historically, it tends to even out and the margins sort of come back to those averages that we see. Got it. Super. Thank you so much. Thank you. You're welcome. Thanks, Bob. Our next question comes from the line of Mark Connelly with Stephens. Please proceed with your question. Thanks. If we start with the human side, I was hoping you could help us understand where the volume growth is coming from in terms of, is it higher volumes on existing customer products or is it new launches? It feels like product launches are accelerating, so I'm just curious what your perspective is then. Mark Connelly, I'll take that one. It really is somewhat across the board, I would have to say. If you peel the onion back and look at all of our product lines, all of our sub-businesses within what we call Human Nutrition and Health, essentially they all grew in the Q1. Obviously, some more than others, but they all grew. There was significant growth of existing products with just increased demand for existing products in the marketplace. Certainly in the minerals and nutrients, that's being driven by increased awareness around nutrition and the immunity-boosting nature of many of our products. Those are essentially existing products with increased demand. In the food side, we are seeing the pickup in food service, and those are really existing products that are selling to a greater extent. We also are seeing our customers launch new products. For example, in the quarter, we've talked about some of Danone's products historically. They launched some product line extensions that also include our VitaCholine. They're launching new products. They're having success with some of those initial products. The Horizon brand of milk, for example, that's fortified with choline. They've come out with a yogurt pouch, for example, and a yogurt drink. Gerber has sold baby puffs for some time. They're now selling some baby puffs with VitaCholine. I'd call that a product line extension. We are seeing some benefits from new products being launched to consumers that are including our products. I would say overall, it's a mix both of just increased sales of existing products as well as launches of new consumer products, and not so much launches of new fundamental products by Balchem. We do have a few that are making it to the market, but not materially impacting things at this point. It's mostly sales of existing products and then our customers launching new products that we're benefiting from. Right. Well, we've heard a lot of folks express concern that the immunity boosting stuff would fall off, so it's nice to hear that it hasn't. Can you talk a bit about the EO products for agriculture? I know it's a small piece of the pie, but I'm just curious how much of a resource investment it is for you and where you're going with it. Yeah, I think that when we talk about our specialty product segment, and I'm just going to maybe guess a little bit where you're headed here on the specialty product side, when we talk about plant nutrition. Those really are chelated minerals for plant nutrition. We're not really selling any, I think you mentioned EO products for. Oh, yeah. Sorry. Ag market. That's not something we do. Within specialty products, we have a really nice, profitable plant nutrition business that we view as a growth business, one that we can continue to grow at double-digit rates. One thing that has been a struggle with that business at times is weather. For the last couple of years, weather has cooperated, and we've been able to drive double-digit growth, and we're quite bullish about that business. We have some very differentiated micronutrient solutions for the marketplace, and we have launched some of our Balchem new products there, and those are making a difference. We just have enormous opportunity to grow just through market penetration, adding additional crops, as well as geographic expansion. That is one business we have a good representation around the globe, and there's a lot of room for us to grow geographically there. We are bullish on that. In the Q1 of the year, actual sales were down slightly, partly because Q1 of last year was particularly strong, but also because of Q1 this year, some orders leaked into Q2. We feel really good about full-year growth for our plant nutrition business and continue to feel as though we can grow that business nicely, despite the fact that Q1 was not the strongest for that business. That's helpful. I guess I'm so excited that I was jumping ahead to my next question. My next question was about EO. I'm curious how you think the normalization of hospital activity is going to affect. Are we going to see a bump here, a bump up or a bump down? We believe overall we're going to see a bump up as opposed to a bump down. You're sort of digging into a very important topic relative to this and very kind of pertinent to what's happening today. We did see really nice growth sequentially in our what we call performance gases business. Volume was up about 11% sequentially, which is a nice bump. We've seen some sequential improvement. Q4 was up a little bit over Q3. We are seeing nice sequential improvement, which is very good to see. We do think there probably is a little bit of a supply chain inventory building aspect to that increase in Q1 because of the anticipation of return to elective surgery. I think in advance of that return, we see the supply chain placing orders, building a little bit of inventory, which is all very encouraging and what we're seeing from statistics in the market as well. We'll have to see this strong Q1 that we're really pleased with, that sequential improvement. Was some of that driven by inventory building in the supply chain or not? If you step back from that, we believe that we'll see Q2 of this year being up over Q2 of last year, Q3 of this year being up over Q3 of last year, and that trend going on throughout the year as elective surgeries come back. I think it's a bump up except for a little asterisk that I kind of pointed that detail around the building and the supply chain. Overall, we feel good about the return of that business. Super helpful. Thank you. Yeah. Thanks, Mark. Appreciate it. Thank you. Our next question comes from the line of Mitra Ramgopal with Sidoti & Company. Please proceed with your question. Yes. Hi. Good morning, guys. Thanks for taking the questions. First, just coming back on the margin side, obviously, I think on the raw material side, it seems like the price increases should mitigate much of the impact there. I was curious on the increase in distribution costs that you're seeing, what can you do to kind of stem that, and then should we sort of expect that to maybe normalize for you? Hi, Mitra. I mean, certainly a challenge at the moment with the inflation going on. Just to maybe dimensionalize it a little bit, if you just look at sort of price paid year-over-year in Q1 this year versus Q1 last year for the exact same product, that impact is $4.5 million, almost $4.5 million of just increased price paid for the same thing. It's very relevant. Same thing on the distribution costs. I mean, we have seen almost half a percentage point, so call it 50 basis points impact to our gross margin just from increased distribution costs coming from A lot on the international shipment side, shortage of containers. As we have negotiated rates and those things, but they're not available, so you have to go to your second, third, fourth option and then pay a higher price. Your first option just kind of declines your order. To your question, sort of what can we do about that distribution side? I think it's a little bit challenging for us to do much to reduce that cost. It's a little bit supply and demand situation right now. The industry has been disrupted. Demand is high, supply is low. While we have negotiated rates and partners and so on, there's a limit to what we can do there. We're really more focused on how do we take the increased costs and turn around and effectively pass them through to our customers. At the end of the day, that's where we're looking for the recovery because we are somewhat limited in how we can manage the input costs in this case. Okay. No, that's great. On the, obviously, pandemic with the vaccine rollout underway and restrictions being increasingly lifted, et cetera, we probably should expect specialty products business to bounce back as per vintage and start growing year-over-year. On the human nutrition side, I'm just curious, especially on the food service market, a lot of restaurants, et cetera, also likely starting to see improved business. Is any of that showing up for you yet, or is it still way too early? No, it is, Mitra. We've talked about, we have approximately $50 million-$60 million of sales, or we did at least in 2019, that went into food service that really was significantly impacted. We are absolutely seeing an increase in that business. It's still volatile. It's still not consistent. We are seeing that business come back in an encouraging way. We have all along had, as part of our human and nutrition health business, really across Balchem as a whole, parts of the company that were negatively impacted by COVID-19 and parts that were positively impacted by COVID-19. We've talked about Keurig Dr Pepper and the business that we have with them, likely there being a work from home boost to that business that helped us offset some of that decline that we saw in food service. By and large, those parts that have been somewhat benefited by the pandemic, we're seeing continue at very strong levels. There are reasons to think that that will continue. I personally feel as though on the supplement side of things, that the strength and awareness that has been built over the last year will largely continue. We're expecting continued strength in that business, and I think Keurig Dr Pepper just issued their results, and I think they're very bullish about the year as well, and I think there's some staying power for that business. There is, as we see food service come back more over the course of the year, there is some positive offset to any decline that we might happen to see from those other areas. We do feel good about the H&H business for the rest of the year. Okay. No, that's great. Just finally, you've obviously done a great job on the balance sheet, steadily paying down debt, net sort of building cash. Just curious in terms of the acquisition pipeline and if you're maybe seeing some opportunities now that might not have existed pre-COVID. We definitely, and I think I said these exact same words, there was definitely a short slowdown last year in the early stages of pandemic. We even as a company struggle a little bit with how could we do a transaction. I think that the market, as everybody will tell you, is very hot. There are lots of assets for sale. We are back active. We've been involved in some processes that have not turned out, whether it ultimately didn't make sense for us strategically or we didn't think the value was appropriate. We're active. The pipeline, I think is healthy. I think we're interested to see if some of the proposed tax legislation has an impact on private companies, which is somewhat of a target for us, and their desire to monetize today versus in the future under a different tax structure. We're somewhat hopeful that that may bring some assets to the table. We're busy, we're active, and encouraged about the opportunities out there. Okay. That's great. Thanks for taking the questions. Thanks, Mitra. Appreciate it. Thanks, Mitra. Thank you. Ladies and gentlemen, at this time, I would like to turn the floor back to partners for closing comments. Thanks, Jen. Once again, just would like to thank everybody for joining our call today and more importantly, your continued interest in our company. We're really pleased with our Q1 2021 results that we released today and the ongoing progress we're making on our key growth initiatives. As a reminder, please go to our website to look at our new sustainability report. We're really proud of it, and I think you will be as well. We appreciate your time today and look forward to reporting out on Q2 results in July. In the meantime, we will be presenting at several conferences. We're going to be at the Wells Fargo Industrials Conference on May 6th, the Stephens Food and Ag Disruptive Conference on May 25th, and the Jefferies Industrials Conference in August. We hope to see some of you at one of those events or in some other forum. Thanks again for joining today. Appreciate it. Thank you. Ladies and gentlemen, this concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.